Table 2 Summary of efficacy for triple antiplatelet therapy in randomised controlled trials (significant effects are in bold).
From: Triple antiplatelet therapy for preventing vascular events: a systematic review and meta-analysis
Patients | Intervention | Myocardial infarction | Composite vascular event | Death | ||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Â | Â | Triple events/total | Control events/total | OR* (95% CI) | Triple events/total | Control events/total | OR* (95% CI) | Triple events/total | Control events/total | OR* (95% CI) |
NSTE-ACS | GP IIb/IIIa | 195/1848 | 232/1558 | 0.70 (0.56-0.88) | 202/1848 | 244/1558 | 0.69 (0.55-0.86) | 14/1848 | 19/1558 | 0.72 (0.36-1.43) |
STEMI | GP IIb/IIIa | 32/1771 | 117/1683 | 0.26 (0.17-0.38) | 88/1771 | 203/1683 | 0.39 (0.30-0.51) | 56/1771 | 78/1683 | 0.69 (0.49-0.99) |
| Â | Cilostazol | 2/30 | 1/30 | 2.07 (0.18-24.15) | Â | Â | Â | Â | Â | Â |
Elective PCI | GP IIb/IIIa | 170/3615 | 244/3614 | 0.77 (0.54-1.11) | 195/3515 | 268/3514 | 0.78 (0.54-1.12) | 33/3515 | 37/3514 | 0.90 (0.55-1.46) |
| Â | Cilostazol | 17/1439 | 16/1437 | 1.07(0.53-2.16) | 46/1408 | 57/1409 | 0.86(0.40-1.85) | 20/1439 | 29/1437 | 0.70(0.39-1.25) |
| Â | Clopidogrel | 2/60 | 2/60 | 0.95 (0.13-6.74) | Â | Â | Â | Â | Â | Â |